XL228 by Exelixis is a mulittargeted Kinase Inhibitor that targets several kinases including ALK. It has either completed or is near completing a phase I trial.
There are two phase I clinical trials for XL228. The first is for solid tumors (including NSCLC). See http://www.clinicaltrials.gov/ct2/show/NCT00526838?term=XL228&rank=1
The second trial is for Leukemia. See http://www.clinicaltrials.gov/ct2/show/NCT00464113?term=XL228&rank=2 .
Here is a link to an ASCO abstract that summarizes the initial result from a Phase I trial of XL228. 41 patients were enrolled (having various kinds of tumors). Apparantly 5 of 9 (56%) of NSCLC patients experienced stable disease for greater than 12 weeks (up to 29 weeks). The abstract does not break out results by ALK status.
You must be logged in to post a comment.